Sotera Health (NASDAQ:SHC) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. grew its position in shares of Sotera Health (NASDAQ:SHC) by 504.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,192 shares of the company’s stock after purchasing an additional 3,498 shares during the period. Blue Trust Inc.’s holdings in Sotera Health were worth $57,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Sotera Health by 2.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company’s stock valued at $711,000 after purchasing an additional 1,047 shares during the period. GAMMA Investing LLC lifted its holdings in Sotera Health by 37.5% during the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after buying an additional 1,121 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in Sotera Health by 3.5% during the 3rd quarter. New York State Teachers Retirement System now owns 53,500 shares of the company’s stock worth $893,000 after buying an additional 1,800 shares in the last quarter. True Wealth Design LLC purchased a new position in Sotera Health in the 3rd quarter valued at approximately $32,000. Finally, First Citizens Bank & Trust Co. grew its stake in shares of Sotera Health by 16.8% in the fourth quarter. First Citizens Bank & Trust Co. now owns 16,689 shares of the company’s stock worth $228,000 after acquiring an additional 2,402 shares in the last quarter. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on SHC shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research note on Thursday, November 21st. Citigroup increased their price target on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. The Goldman Sachs Group initiated coverage on Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective for the company. Finally, Barclays cut their target price on shares of Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $16.08.

Sotera Health Stock Up 1.9 %

Shares of NASDAQ SHC opened at $13.73 on Wednesday. The business has a 50-day moving average of $13.48 and a two-hundred day moving average of $14.54. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 54.92 and a beta of 1.91. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.